MedTrace Logo

Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction

NCT00062374 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2017-07-06

Study results available
· View outcomes & findings →

Summary

This phase II trial is studying how well giving irinotecan together with cisplatin works in treating patients who are undergoing surgical resection for locally advanced cancer of the stomach or gastroesophageal junction. Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug and giving them before surgery may shrink the tumor so that it can be removed during surgery.

Conditions

  • Gastric Adenocarcinoma
  • Stage II Gastric Cancer
  • Stage III Gastric Cancer
  • Stage IV Gastric Cancer

Interventions

DRUG

Cisplatin

Given IV

PROCEDURE

Computed Tomography

Undergo FDG and FLT PET/CT

RADIATION

Fludeoxyglucose F-18

Undergo FDG-PET/CT

OTHER

Fluorothymidine F-18

Undergo FLT-PET/CT

DRUG

Irinotecan Hydrochloride

Given IV

PROCEDURE

Positron Emission Tomography

Undergo FDG and FLT PET/CT

PROCEDURE

Therapeutic Conventional Surgery

Undergo radical subtotal or total gastrectomy with lymph node dissection

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Manisha Shah · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00062374 on ClinicalTrials.gov